A comprehensive overview of the leading peptides used in growth hormone axis research, including GHRH analogs, secretagogues, combination approaches, and laboratory best practices.
Part of the PeptidesATX Research Hub
The growth hormone (GH) axis is one of the most extensively studied endocrine signaling pathways in biomedical research. The hypothalamic-pituitary axis regulates GH secretion through a complex interplay of stimulatory and inhibitory signals, primarily growth hormone-releasing hormone (GHRH) and somatostatin, respectively.
Researchers investigating the GH axis rely on synthetic peptides that target specific nodes of this signaling cascade. These research peptides fall into two principal categories: GHRH analogs that mimic the natural releasing hormone, and growth hormone secretagogues (GHS) that activate the ghrelin receptor pathway. Understanding the distinctions between these classes is fundamental to designing rigorous GH research protocols.
The GH axis operates through pulsatile secretion patterns, with the anterior pituitary releasing GH in response to hypothalamic signaling. This pulsatility is critical to research design, as the timing and amplitude of GH pulses influence downstream effects including hepatic IGF-1 production. The best peptides for growth hormone research are those that allow investigators to precisely modulate these signaling pathways under controlled laboratory conditions.
Growth hormone-releasing hormone analogs are synthetic peptides designed to mimic or enhance the activity of endogenous GHRH. These compounds bind to the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary, initiating a cAMP-dependent signaling cascade that promotes GH gene transcription, synthesis, and secretion.
CJC (No Dac) is a synthetic 30-amino-acid GHRH analog with significant modifications to enhance metabolic stability. The peptide is available in two principal forms: CJC (No Dac) with Drug Affinity Complex (DAC), which binds to serum albumin for extended half-life, and CJC (No Dac) without DAC (also called Modified GRF 1-29), which retains the core GHRH activity with improved resistance to enzymatic degradation.
Key structural modifications in CJC (No Dac) include amino acid substitutions at positions 2, 8, 15, and 27 of the native GHRH sequence. These changes protect the peptide from dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary degradation pathway of endogenous GHRH. Laboratory research has demonstrated that CJC (No Dac) maintains receptor binding affinity while achieving substantially greater plasma stability than the native hormone.
CJC (No Dac) is frequently studied in combination with Ipamorlin. Explore our CJC (No Dac)/Ipamorlin research blend for laboratory applications.
Tesa is a synthetic GHRH analog consisting of the full 44-amino-acid human GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification enhances metabolic stability while preserving the complete receptor-binding domain of native GHRH.
Among GHRH analogs, Tesa is notable for being one of the most extensively studied in clinical research contexts. Its mechanism involves direct activation of the GHRH receptor, stimulating pulsatile GH release that closely resembles physiological secretion patterns. Researchers utilize Tesa to investigate GHRH receptor pharmacology and GH axis modulation with high specificity.
Serma (GRF 1-29) is a 29-amino-acid peptide representing the shortest fully functional fragment of human GHRH. It contains the essential N-terminal bioactive region required for GHRH receptor binding and activation. As the first synthetic GHRH analog developed for research, Serma established much of the foundational understanding of GHRH receptor pharmacology.
While Serma has a shorter half-life compared to modified analogs like CJC (No Dac), this characteristic is advantageous in certain research designs where investigators require rapid onset and clearance to study acute GH pulse dynamics. Its well-characterized pharmacological profile makes it a reliable reference compound in comparative GH peptide studies.
Growth hormone secretagogues (GHS) represent a distinct class of GH-releasing peptides that act through the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike GHRH analogs, these compounds activate a phospholipase C-dependent intracellular signaling pathway, providing a complementary mechanism of GH release.
Ipamorlin is a pentapeptide GH secretagogue notable for its high selectivity for the GHS-R1a receptor. Research has demonstrated that Ipamorlin stimulates GH release with minimal effects on other pituitary hormones such as ACTH, cortisol, or prolactin. This selectivity distinguishes it from earlier-generation secretagogues and makes it a preferred tool in laboratory studies requiring isolated GH pathway investigation.
The amino acid sequence of Ipamorlin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporates unnatural amino acids that confer both receptor selectivity and resistance to enzymatic degradation. Preclinical studies have demonstrated dose-dependent GH release with a characteristic bell-shaped response curve, providing researchers with a predictable pharmacological tool for GH axis studies.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide secretagogue that was among the first synthetic GHS compounds identified. It activates the GHS-R1a receptor with strong efficacy, producing robust GH release in preclinical models. However, unlike Ipamorlin, GHRP-6 research has also demonstrated effects on appetite signaling, cortisol, and prolactin levels, reflecting its broader receptor interaction profile.
In the laboratory setting, GHRP-6 remains valuable for comparative studies examining receptor selectivity differences among GH secretagogues. Its well-documented pharmacology provides a benchmark against which newer, more selective compounds like Ipamorlin can be evaluated.
One of the most active areas of GH peptide research involves combination protocols using CJC (No Dac) and Ipamorlin. The scientific rationale for this combination stems from the complementary mechanisms of GHRH receptor activation and ghrelin receptor activation.
When studied together, CJC (No Dac) (acting via the GHRH-R/cAMP pathway) and Ipamorlin (acting via the GHS-R1a/PLC pathway) converge on somatotroph cells through independent intracellular signaling cascades. Preclinical research suggests this dual-pathway stimulation may produce synergistic GH release that exceeds the additive effects of either compound alone.
Key observations from combination research include:
Our CJC (No Dac)/Ipamorlin 5mg/5mg blend is formulated specifically for researchers investigating these dual-pathway interactions in controlled laboratory settings.
Insulin-like Growth Factor 1 (IGF-1) is the principal downstream mediator of growth hormone signaling and plays a central role in GH axis research. GH stimulates IGF-1 production primarily in the liver, and circulating IGF-1 levels serve as a key biomarker of GH axis activity in research protocols.
IGF-1 exerts its biological effects through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates two major intracellular signaling cascades:
In the context of GH-releasing peptide research, IGF-1 measurements provide investigators with a functional readout of GH axis activation. Researchers studying GHRH analogs and secretagogues frequently assess IGF-1 levels as an endpoint to evaluate the downstream efficacy of GH-releasing compounds. Additionally, IGF-1 itself is studied as a research peptide for investigating growth factor receptor biology and intracellular signaling networks.
Selecting the appropriate peptide for GH research depends on the specific experimental questions being addressed. The following comparison highlights key characteristics relevant to laboratory investigators. For a detailed head-to-head analysis, see our CJC (No Dac) vs Tesa comparison.
| Peptide | Class | Receptor Target | Key Research Advantage |
|---|---|---|---|
| CJC (No Dac) (DAC) | GHRH Analog | GHRH-R | Extended half-life via albumin binding; sustained GH elevation studies |
| CJC (No Dac) (no DAC) | GHRH Analog | GHRH-R | DPP-IV resistant; pulsatile GH release research |
| Tesa | GHRH Analog | GHRH-R | Full-length GHRH sequence; most clinically characterized |
| Serma | GHRH Analog | GHRH-R | Shortest bioactive fragment; rapid clearance for acute studies |
| Ipamorlin | GH Secretagogue | GHS-R1a | High selectivity; minimal off-target hormone effects |
| GHRP-6 | GH Secretagogue | GHS-R1a | Robust GH release; broad receptor profile for comparative studies |
| IGF-1 | Growth Factor | IGF-1R | Downstream GH mediator; direct growth factor signaling research |
Each peptide offers distinct advantages depending on the research context. GHRH analogs are preferred for studying the canonical GH-releasing pathway, secretagogues for ghrelin receptor pharmacology, and IGF-1 for downstream signaling investigations.
Proper handling and preparation of GH research peptides is essential for maintaining compound integrity and ensuring experimental reproducibility. The following guidelines apply to all peptides discussed in this guide.
All GH research peptides are supplied as lyophilized powders and require reconstitution prior to use. Follow these laboratory protocols for optimal results:
For detailed step-by-step instructions, refer to our complete peptide reconstitution guide.
Research dosing protocols vary based on the experimental model, peptide type, and study objectives. Key considerations include:
The reliability of growth hormone peptide research depends directly on the quality and purity of the compounds used. When sourcing GH research peptides, investigators should verify the following quality indicators:
Sourcing from suppliers that provide comprehensive COA documentation and maintain cGMP-aligned manufacturing practices is essential for generating reproducible, publication-quality data. Browse our complete catalog of research-grade GH peptides with batch-specific quality documentation.
The most commonly studied peptides for growth hormone research include GHRH analogs such as CJC (No Dac), Tesa, and Serma, as well as growth hormone secretagogues like Ipamorlin and GHRP-6. Researchers frequently investigate these compounds individually and in combination to understand their effects on GH release, pulsatility, and downstream IGF-1 signaling pathways.
GHRH analogs such as CJC (No Dac) and Serma mimic the natural growth hormone-releasing hormone and act on GHRH receptors in the anterior pituitary to stimulate GH synthesis and release. Growth hormone secretagogues like Ipamorlin and GHRP-6 act on the ghrelin receptor (GHS-R1a) through a separate mechanism. These two classes work through distinct but complementary pathways, which is why combination research protocols are of significant interest.
CJC (No Dac) and Ipamorlin are studied together because they act through complementary mechanisms. CJC (No Dac) is a GHRH analog that stimulates GH release via the GHRH receptor, while Ipamorlin is a selective ghrelin receptor agonist. Preclinical research suggests that combining both pathways may produce a synergistic effect on GH pulsatility that exceeds what either peptide achieves alone. This dual-pathway approach is a major area of ongoing laboratory investigation.
Lyophilized GH research peptides should be stored at -20°C or below, protected from light and moisture. For reconstitution, use bacteriostatic water and inject it slowly along the vial wall to avoid denaturing the peptide. Once reconstituted, keep the solution refrigerated at 2-8°C, protected from light, and use it promptly; no product-specific post-reconstitution stability data is available, so no duration is stated. Minimize freeze-thaw cycles to preserve peptide integrity. See our complete peptide reconstitution guide for step-by-step instructions.
IGF-1 (Insulin-like Growth Factor 1) is a key downstream mediator of growth hormone signaling. In research settings, IGF-1 levels are frequently measured as a biomarker of GH axis activity. GH stimulates hepatic IGF-1 production, and IGF-1 in turn activates the PI3K/Akt and MAPK/ERK signaling cascades. Researchers study IGF-1 both as an indicator of GH-releasing peptide efficacy and as a research compound in its own right for understanding growth factor biology.
Access quality documentation and research-grade growth hormone peptides for your laboratory investigations.
View Certificates of Analysis Explore Research-Grade GH PeptidesDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use. No statements herein constitute medical claims or therapeutic recommendations. Researchers are responsible for ensuring compliance with all applicable regulations governing the purchase and use of research peptides in their jurisdiction.